**Core Concept**
Thiazolidinediones (TZDs) are a class of medications used in the treatment of type 2 diabetes mellitus. They work by activating the peroxisome proliferator-activated receptor-gamma (PPAR-γ), which regulates glucose and lipid metabolism.

**Why the Correct Answer is Right**
TZDs increase the risk of heart failure by promoting sodium retention, increasing fluid overload, and enhancing fibrosis in the heart. This is due to the activation of PPAR-γ, which leads to increased expression of genes involved in sodium transport and fluid balance. Additionally, TZDs can increase cardiac preload and afterload, further contributing to the risk of heart failure.

**Why Each Wrong Option is Incorrect**
**Option A:** Nephrotic syndrome - While TZDs can cause fluid retention and edema, they are not primarily associated with nephrotic syndrome.
**Option B:** Hypoglycemia - TZDs actually increase insulin sensitivity, which would decrease the risk of hypoglycemia.
**Option C:** Lactic acidosis - This is more commonly associated with biguanides (metformin), not thiazolidinediones.

**Clinical Pearl / High-Yield Fact**
TZDs can increase the risk of heart failure, particularly in patients with pre-existing cardiovascular disease. This risk is dose-dependent and can be mitigated by careful patient selection and monitoring.

**Correct Answer: C. Heart failure.**